The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
DNA vaccine for cancer immunotherapy
Open accessAbstract
DNA vaccination has emerged as an attractive immunotherapeutic approach against cancer due to its simplicity, stability, and safety. Results from numerous clinical trials have demonstrated that DNA vaccines are well tolerated by patients and do not trigger major adverse effects. DNA vaccines are also very cost effective and can be administered repeatedly for long-term protection. Despite all the practical advantages, DNA vaccines face challenges in inducing potent antigen specific cellular immune responses as a result of immune tolerance against endogenous self-antigens in tumors. Strategies to enhance immunogenicity of DNA vaccines against self-antigens have been investigated including encoding of xenogeneic versions of antigens, fusion of antigens to molecules that activate T cells or trigger associative recognition, priming with DNA vectors followed by boosting with viral vector, and utilization of immunomodulatory molecules. This review will focus on discussing strategies that circumvent immune tolerance and provide updates on findings from recent clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 2×
“Furthermore, it was also demonstrated that intramuscular injection of plasmid DNA can lead to long term gene expression and elicit both humoral and cellular immune responses against the encoded antigen.(2,3) These studies have sparked the development of DNA vaccines against various diseases including influenza and HIV…”
BackgroundA Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“These signaling pathways were shown to be essential in the activation of antigen specific T cells and B cells.(50,51) DNA vaccines can be delivered intradermally with devices like Gene Gun, leading to transfection of epidermal keratinocytes and Langerhans cells.”
BackgroundHeterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Fynan, E. F., Webster, R. G., Fuller, D. H., Haynes, J. R., Santoro, J. C., & Robinson, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11478 · Cited by 1,115
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Gene transfer into muscle by electroporation in vivo
Aihara, H., & Miyazaki, J.-I. (1998) · Nature Biotechnology · doi:10.1038/nbt0998-867 · Cited by 944
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Jäger, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.2.265 · Cited by 725
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Gene inoculation generates immune responses against human immunodeficiency virus type 1.
Wang, B., Ugen, K. E., Srikantan, V, Agadjanyan, M. G., Dang, K., Refaeli, Y., Sato, A. I., Boyer, J., Williams, W. V., & Weiner, D. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4156 · Cited by 655
MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J., Ciccarelli, R. B., et al. (1998) · Journal of Infectious Diseases · doi:10.1086/515613 · Cited by 640
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines
Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., Takeshita, F., Coban, C., et al. (2008) · Nature · doi:10.1038/nature06537 · Cited by 628
Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo
Widera, G., Austin, M., Rabussay, D., Goldbeck, C., Barnett, S. W., Chen, M., Leung, L., Otten, G. R., Thudium, K., Selby, M. J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4635 · Cited by 606
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
Porgador, A., Irvine, K. R., Iwasaki, A., Barber, B. H., Restifo, N. P., & Germain, R. N. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1075 · Cited by 560
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Raz, E., Carson, D. A., Parker, S. E., Parr, T. B., Abai, A. M., Aichinger, G., Gromkowski, S. H., Singh, M., Lew, D., & Yankauckas, M. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9519 · Cited by 543
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Electroporation delivery of DNA vaccines: prospects for success
Sardesai, N. Y., & Weiner, D. B. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.008 · Cited by 416
DNA vaccines: precision tools for activating effective immunity against cancer
Rice, J., Ottensmeier, C. H., & Stevenson, F. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2326 · Cited by 415
Skipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V, Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.527 · Cited by 405
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination
Desmet, C. J., & Ishii, K. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3247 · Cited by 392
Tumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
Electropermeabilization of skeletal muscle enhances gene transfer in vivo
Mathiesen, I. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300847 · Cited by 372
DNA Vaccination: Transfection and Activation of Dendritic Cells as Key Events for Immunity
Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., & Stockinger, B. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.1.169 · Cited by 361
Bergman, P. J., McKnight, J. A., Novosad, A., Charney, S. C., Farrelly, J., Craft, D. M., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A. E., et al. (2003) · PubMed · Cited by 330
An Antigenic Peptide Produced by Peptide Splicing in the Proteasome
Vigneron, N., Stroobant, V., Chapiro, J., Ooms, A., Degiovanni, G., Morel, S., van der Bruggen, P., Boon, T., & Van den Eynde, B. J. (2004) · Science · doi:10.1126/science.1095522 · Cited by 330
Distribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice
Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M. J., Chen, M., Otten, G. R., Ulmer, J. B., Donnelly, J. J., Ott, G., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2850 · Cited by 327 · cited 2×
“However, scaling up from mice to human subjects, the low transfection efficiency means that a large amount of DNA would need to be applied, making such an approach impractical.(58) A potential solution to this problem is electroporation (EP).”
BackgroundCasares, S., Inaba, K., Brumeanu, T.-D., Steinman, R. M., & Bona, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1481 · Cited by 317
Fu, T.-M., Ulmer, J. B., Caulfield, M. J., Deck, R. R., Friedman, A., Wang, S., Liu, X., Donnelly, J. J., Liu, M. A., & Wigzell, H. (1997) · Molecular Medicine · doi:10.1007/bf03401683 · Cited by 296
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
How will HPV vaccines affect cervical cancer?
Roden, R., & Wu, T.-C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1973 · Cited by 283
Self-citationImmunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
Wang, R.-F., Appella, E., Kawakami, Y., Kang, X., & Rosenberg, S. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2207 · Cited by 272
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways
Leitner, W. W., Hwang, L. N., deVeer, M. J., Zhou, A., Silverman, R. H., Williams, B. R. G., Dubensky, T. W., Ying, H., & Restifo, N. P. (2003) · Nature Medicine · doi:10.1038/nm813 · Cited by 269
Maldonado, L., Teague, J. E., Morrow, M. P., Jotova, I., Wu, T. C., Wang, C., Desmarais, C., Boyer, J. D., Tycko, B., Robins, H. S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007323 · Cited by 255
Self-citationWang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1131 · Cited by 255
Nauts, H. C., FOWLER, G. A., & Fh, B. (1953) · PubMed · Cited by 247
Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethé, B., Jotereau, F., & Boon, T. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1173 · Cited by 230
Chattergoon, M. A., Robinson, T. M., Boyer, J. D., & Weiner, D. B. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5707 · Cited by 222
Translating Tumor Antigens into Cancer Vaccines
Buonaguro, L., Petrizzo, A., Tornesello, M. L., & Buonaguro, F. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00286-10 · Cited by 219
Ledwith, B. J., Manam, S., Troilo, P. J., Barnum, A. B., Pauley, C. J., Griffiths II, T. G., Harper, L. B., Beare, C. M., Bagdon, W. J., & Nichols, W. W. (2000) · Intervirology · doi:10.1159/000053993 · Cited by 218
Trimble, C. L., Peng, S., Kos, F., Gravitt, P., Viscidi, R., Sugar, E., Pardoll, D., & Wu, T. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1725 · Cited by 209
Self-citationDNA Vaccines: Developing New Strategies against Cancer
Fioretti, D., Iurescia, S., Fazio, V. M., & Rinaldi, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/174378 · Cited by 202
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
Cohen, A. D., Diab, A., Perales, M.-A., Wolchok, J. D., Rizzuto, G., Merghoub, T., Huggins, D., Liu, C., Turk, M. J., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2813 · Cited by 202
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117208109 · Cited by 200
Central tolerance: good but imperfect
Gallegos, A. M., & Bevan, M. J. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00348.x · Cited by 198
Trimble, C., Lin, C.-T., Hung, C.-F., Pai, S., Juang, J., He, L., Gillison, M., Pardoll, D., Wu, L., & Wu, T.-C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00275-5 · Cited by 192
Self-citationElectroporation improves the efficacy of DNA vaccines in large animals
BABIUK, S. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00269-4 · Cited by 183
Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I., Stevenson, F., & Ottensmeier, C. H. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.067 · Cited by 179
Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review
Berinstein, N. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.017 · Cited by 158
Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases
FULLER, D. H., Loudon, P. T., & Schmaljohn, C. S. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.022 · Cited by 155
Adjuvant Activity of CpG Oligodeoxynucleotides
Klinman, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600743057 · Cited by 148
Gene Transfer into Muscle by Electroporation In Vivo
Miyazaki, J., & Aihara, H. (2003) · Humana Press eBooks · doi:10.1385/1-59259-141-8:049 · Cited by 140
Ahlén, G., Söderholm, J., Tjelle, T. E., Kjeken, R., Frelin, L., Höglund, U., Blomberg, P., Fons, M. P., Mathiesen, I., & Sällberg, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4741 · Cited by 135
Yao, J., Caballero, O. L., Yung, W. K. A., Weinstein, J. N., Riggins, G. J., Strausberg, R. L., & Zhao, Q. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0088 · Cited by 129
Gregor, P. D., Wolchok, J. D., Ferrone, C. R., Buchinshky, H., Guevara-Patino, J. A., Perales, M., Mortazavi, F., Bacich, D. J., Heston, W., Latouche, J., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.10.048 · Cited by 127
Norell, H., Poschke, I. C., Charo, J., Wei, W. Z., Erskine, C. L., Piechocki, M. P., Knutson, K. L., Bergh, J. C. S., Lidbrink, E. K., & Kiessling, R. W. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-53 · Cited by 127
Liu, J., Kjeken, R., Mathiesen, I., & Barouch, D. H. (2008) · Journal of Virology · doi:10.1128/jvi.02564-07 · Cited by 127
Becker, J. T., Olson, B. M., Johnson, L. E., Davies, J. G., Dunphy, E. J., & McNeel, D. G. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dda23e · Cited by 120
Multiple tumour-specific antigens expressed on a single tumour cell
Wortzel, R. D., Philipps, C., & Schreiber, H. W. (1983) · Nature · doi:10.1038/304165a0 · Cited by 108
Chudley, L., McCann, K. J., Mander, A., Tjelle, T. E., Campos-Pérez, J. J., Godeseth, R., Creak, A., Dobbyn, J., Johnson, B., Bass, P., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1270-0 · Cited by 107
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures
Bendandi, M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2717 · Cited by 100
Weber, J. S., Boswell, W. D., Smith, J. W., Hersh, E. M., Snively, J., Diaz, M. I., Miles, S., Liu, X., Obrocea, M., Qiu, Z., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181611420 · Cited by 82
Diaz, C. M., Chiappori, A., Aurisicchio, L., Bagchi, A., Clark, J., Dubey, S. A., Fridman, A., Fabregas, J. C., Marshall, J. L., Scarselli, E., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-62 · Cited by 80
Yuan, J. D., Ku, G. Y., Gallardo, H. F., Orlandi, F., Manukian, G., Rasalan, T. S., Xu, Y., Li, H., Vyas, S., Mu, Z., et al. (2009) · PubMed · Cited by 79
DNA tumor viruses and human cancer
Damania, B. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.11.002 · Cited by 70
Cancer Genome Sequencing—An Interim Analysis
Fox, E., Salk, J. J., & Loeb, L. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1231 · Cited by 70
Jaramillo, A., Majumder, K., Manna, P. P., Fleming, T. P., Doherty, G. M., DiPersio, J. F., & Mohanakumar, T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10736 · Cited by 70
Ginsberg, B. A., Gallardo, H. F., Rasalan, T. S., Adamow, M. J., Mu, Z., Tandon, S., Bewkes, B. B., Roman, R.-A., Chapman, P. B., Schwartz, G. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1093 · Cited by 69
Staff, C., Mozaffari, F., Hallermalm, K., Wahrén, B., & Liljefors, M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.063 · Cited by 64
Daniel, C. W., Berger, J. J., Strickland, P. A., & García, R. (1984) · Developmental Biology · doi:10.1016/0012-1606(84)90036-8 · Cited by 64
Yan, J., Pankhong, P., Shin, T. H., Obeng-Adjei, N., Morrow, M. P., Walters, J. N., Khan, A. S., Sardesai, N. Y., & Weiner, D. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0001 · Cited by 62
Tiriveedhi, V., Fleming, T. P., Goedegebuure, P. S., Naughton, M., Ma, C. X., Lockhart, C., Gao, F., Gillanders, W. E., & Mohanakumar, T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2110-9 · Cited by 60
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination
Kobiyama, K., Jounai, N., Aoshi, T., Tozuka, M., Takeshita, F., Coban, C., & Ishii, K. J. (2013) · Vaccines · doi:10.3390/vaccines1030278 · Cited by 60
Towards progress on DNA vaccines for cancer
Lowe, D. B., Shearer, M. H., Jumper, C., & Kennedy, R. C. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7165-0 · Cited by 49
Insufficient APC Capacities of Dendritic Cells in Gene Gun-Mediated DNA Vaccination
Lauterbach, H., Gruber, A., Ried, C., Cheminay, C., & Brocker, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4600 · Cited by 46
The Cancer Testis Antigen PRAME As a Biomarker for Solid Tumor Cancer Management
Goodison, S., & Urquidi, V. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.65 · Cited by 42
DNA Vaccines: A Review of Developments
Webster, R. G., & Robinson, H. L. (1997) · BioDrugs · doi:10.2165/00063030-199708040-00004 · Cited by 41
Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer
Williams, B. B., Wall, M., Miao, Y. R., Williams, B., Bertoncello, I., Kershaw, M. H., Mantamadiotis, T., Haber, M., Norris, M. D., Gautam, A. M., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0497-2 · Cited by 40
Genetic Analysis of Innate Immunity
Hoebe, K. H. N., Jiang, Z., Tabeta, K., Du, X., Georgel, P., Crozat, K., & Beutler, B. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)91005-0 · Cited by 39
Soong, R.-S., Trieu, J., Lee, S. Y., He, L., Tsai, Y.-C., Wu, T. ‐., & Hung, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056912 · Cited by 36
Self-citationSoong, R.-S., Song, L., Trieu, J., Lee, S. Y., He, L., Tsai, Y.-C., Wu, T. ‐., & Hung, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093162 · Cited by 32
Self-citationThe T-cell repertoire available for recognition of self-antigens
Kreuwel, H. T. C., & Sherman, L. A. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(01)00272-2 · Cited by 32
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients
Occhipinti, S., Sponton, L., Rolla, S., Caorsi, C., Novarino, A., Donadio, M., Bustreo, S., Satolli, M. A., Pecchioni, C., Marchini, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2663 · Cited by 29
Ulmer, J. B., & Otten, G. R. (2000) · PubMed · Cited by 25
Aurisicchio, L., Peruzzi, D., Koo, G. C., Wei, W., Monica, N. L., & Ciliberto, G. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.103 · Cited by 23
DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma
Joseph‐Pietras, D., Gao, Y., Zojer, N., Ait‐Tahar, K., Banham, A. H., Pulford, K. A. F., Rice, J., Savelyeva, N., & Sahota, S. S. (2010) · Leukemia · doi:10.1038/leu.2010.196 · Cited by 21
ANTI‐INFLAMMATORY ACTION OF GLUCAGON IN RATS
Leme, J. G., Morato, M., & SOUZA, M. Z. A. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07611.x · Cited by 10
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 493
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Nucleoside modified mRNA vaccines for infectious diseases
Pardi, N., & Weissman, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_6 · Cited by 129
Metadata
- Authors
- Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F.
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-11-02
- Volume
- 10
- Issue
- 11
- Pages
- 3153-3164
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- OpenAlex
- W2011076638
- Cited by
- 276
- References
- 92
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.